Vaccine News and Research

Latest Vaccine News and Research

New vaccine strategy shows promise to protect chickens against serious respiratory disease

A new vaccine strategy could offer protection to millions of chickens threatened by a serious respiratory disease, research shows.

23 Oct 2018

Global HIV Vaccine Enterprise launches strategy to accelerate development of effective HIV vaccine

The Global HIV Vaccine Enterprise, hosted by the International AIDS Society, has launched a five-year strategy to accelerate the development of an effective vaccine to prevent HIV infection.

23 Oct 2018

Could we prevent Alzheimer's disease by treating herpes?

An exciting new paper suggests that over half of all cases of Alzheimer’s disease could be traced back to herpes simplex virus 1, which causes cold sores.

19 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades.

18 Oct 2018

Researchers awarded grant to advance testing of experimental heroin vaccine

Researchers at the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research and SUNY Upstate Medical University in Syracuse, N.Y., have been awarded a grant to advance an experimental heroin vaccine through Phase I/IIa clinical trials to assess both its safety and its efficacy against a morphine challenge.

17 Oct 2018

Scientists develop dual anthrax-plague vaccine

A team of researchers has now engineered a virus nanoparticle vaccine against Bacillus anthracis and Yersinia pestis, tier 1 agents that pose serious threats to national security of the United States. B. anthracis and Y. pestis are the pathogens that cause anthrax and plague, respectively.

16 Oct 2018

WRAIR clinical study evaluates safety and immunogenicity of Marburg vaccine

The Walter Reed Army Institute of Research this week administered the first vaccine in a Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine candidate in healthy adult volunteers.

15 Oct 2018

Who knew? Life begins (again) at 65

I was convinced I would become an adult when I turned 21. But now, I'm certain that turning 65 was the watershed moment that finally grew me up.

15 Oct 2018

Study: School-based HPV vaccination did not increase risky sexual behaviors among adolescent girls

Despite fears to the contrary, sexual behaviors of adolescent girls stayed the same or became safer after publicly funded school-based HPV vaccinations were introduced in British Columbia (BC), according to new research published in CMAJ.

15 Oct 2018

Many parents still skeptical about safety and effectiveness of flu shot, survey finds

When a child gets the flu, they're not only sick in bed for a week or more, but the illness can also have serious and even life-threatening consequences.

15 Oct 2018

Report: Half of parents say young children are afraid of doctor's visits

A trip to the pediatrician's office can be a nerve-wracking experience for both children and their parents, especially when efforts to calm young patients down dominate the visit.

15 Oct 2018

First-of-its-kind study to test a personalized vaccine in cancer patient

Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic.

15 Oct 2018

A new vaccine shows promise in protecting people from rabies, Lassa fever

A novel vaccine designed to protect people from both Lassa fever and rabies showed promise in preclinical testing, according to new research published in Nature Communications.

12 Oct 2018

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

11 Oct 2018